Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by francoisl13on Oct 09, 2023 12:01pm
75 Views
Post# 35675920

RE:RE:News required to move price upwards

RE:RE:News required to move price upwardsWell, if the plant is not ready to produce Coactiv+ as we speak then it is a very poorly execute process. The plant should have been up and ready to produce as soon as the FDA approval was granted. KNE should have been reporting sales in Q3, they didn't so, now the market is waiting for them to report, at a minimum, orders in Q4. Shipment in Q1 2024 will be fine but they need to show that their is some enthusiasm for their product south of the border.
Where did you get that the DispoersinB trail was started? Well, if you know good for you but, so far there is no official announcement from Kane so, I still think that all trials related to DispersinB are still in waiting/negotiating mode, including the UofMiami trials which was suppose to be started in Q3.
If, as you said, the trials have started for DispersinB then, KNE is doing a very poor communication job with the investment community.
P.S. Did you know that they are working on a re-branding of the Coactiv+ brand? If not, you're not on top of it my friend , if you are, well, you must have been in touch with management lately...
GLTA
<< Previous
Bullboard Posts
Next >>